Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock are in focus as the FDA seeks to remove suicide-risk warnings related to their GLP-1 weight-loss drugs. Read more here.

The Food and Drug Administration has upgraded a nationwide cheese recall that includes products sold at major Texas retailers ...

GLP-1 drugs like Ozempic and Mounjaro have significant health benefits for type 1 diabetes, including weight loss, despite ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Wegovy will be heavily subsidised for Australians with severe obesity, who have also experienced a cardiovascular event, like a heart attack or stroke.

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...

In November, the Ambriola Company, a New Jersey-based importer of Italian food products, issued a nationwide recall of more ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

The team of a dozen investigators from the Sheriff’s Office, Pittsfield Police Department and Maine Drug Enforcement Agency ...